Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen s Revenues Nearly Double in Q3

NEW YORK, Nov. 3 (GenomeWeb News) - Nanogen posted a near doubling of revenue in the third quarter, the company said yesterday.  


Nanogen's total revenues for the period ended Sept. 30 increased 191 percent to $3.2 million from $1.1 million in the comparable quarter last year, the company said. Nanogen reported $1.1 million in product revenue for the third quarter of 2005, compared to $671,000 during the same period in 2004.


R&D spending in the period increased 26.7 percent to $5.7 million from $4.5 million year over year.


Nanogen's net loss fell to $8.8 million, or $0.18, from $9.4 million, or $.28 per share year over year.


The company had cash, equivalents, and short-term investments totaling $40.7 million at the end of the recent quarter.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.